MedTrace Logo

Study of Tissue and Blood Samples From Patients With Recurrent Prostate Cancer Who Received Lapatinib on Clinical Trial ECOG-E5803

NCT00897351 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 37

Last updated 2017-05-17

No results posted yet for this study

Summary

RATIONALE: Studying samples of tumor tissue and blood in the laboratory from patients with cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.

PURPOSE: This research study is looking at tissue and blood samples from patients with recurrent prostate cancer who received lapatinib on clinical trial ECOG-E5803.

Conditions

Interventions

GENETIC

mutation analysis

GENETIC

polymorphism analysis

GENETIC

protein expression analysis

OTHER

immunohistochemistry staining method

OTHER

laboratory biomarker analysis

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • ECOG-ACRIN Cancer Research Group

    lead NETWORK

Principal Investigators

  • Jill Kolesar, PharmD · University of Wisconsin, Madison

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-10
Primary Completion
2009-02-10
Completion
2009-02-10

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00897351 on ClinicalTrials.gov